Enasidenib is a targeted drug for relapsed or refractory acute myeloid leukemia (AML) with IDH2 mutations.
Purchase Channels for Enasidenib
Overseas Purchase
(1) Patients may choose to visit hospital pharmacies or authorized retail pharmacies in countries or regions where Enasidenib is approved for sale to inquire about and purchase the medication.
(2) As drug prices may vary due to regional differences, exchange rate fluctuations, and other factors, patients should plan and budget accordingly before purchasing.
Purchase Through Medical Service Agencies
(1) Patients may consult domestic overseas medical service agencies that collaborate with international pharmacies or pharmaceutical companies.
(2) These agencies typically provide access to legitimate import channels and offer professional consultation and guidance.
Precautions for Enasidenib
Strict Adherence to Medical Evaluation and Monitoring
(1) Mutation testing first: Before use, mutation status must be confirmed using an FDA-approved IDH2 detection method (such as the Abbott RealTime IDH2 assay) to avoid ineffective treatment.
(2) Monitoring throughout treatment: Before and during the first three months of treatment, blood counts and blood biochemistry should be checked at least every two weeks, with a focus on monitoring leukocytosis (≥30×10⁹/L) and indicators of tumor lysis syndrome, and adjusting the treatment plan as needed.
Contraindications for Special Populations
(1) Contraindicated during pregnancy: Animal studies have shown that Enasidenib has embryo-fetal toxicity, potentially leading to spontaneous abortion and fetal developmental abnormalities.
(2) Patients of reproductive potential (including males) must use effective non-hormonal contraception during treatment and for two months after the last dose.
(3) Avoid during breastfeeding: The drug may be secreted in breast milk. Breastfeeding should be discontinued during treatment and for two months after stopping the medication.
Drug Interactions
(1) CYP3A substrate drugs (e.g., certain antifungal medications): Concurrent use may reduce the blood concentration of these drugs, leading to treatment failure.
(2) Hormonal contraceptives: Enasidenib may lower their blood concentration. It is recommended to switch to non-hormonal contraceptive methods.
(3) Avoid concurrent use with drugs metabolized by OATP1B1/BCRP transport proteins (e.g., rosuvastatin) to prevent cumulative toxicity.
Authenticity Verification of Enasidenib
Packaging and Tablet Physical Characteristics
(1) Corresponding specifications: Enasidenib tablets are available in 50 mg (oval, film-coated tablets engraved with "ENA50") and 100 mg (capsule-shaped, film-coated tablets engraved with "ENA100"). Genuine products have clear printing on the packaging, complete batch numbers and expiration dates, and include a desiccant inside the bottle.
(2) Official channel verification: Use the traceability code on the drug packaging to check distribution information on the pharmaceutical manufacturer’s official website or official public account.
(3) Shape and engraving: Genuine tablets are light yellow to yellow in color, with clear, unworn engravings. The 50 mg tablets are oval, while the 100 mg tablets are capsule-shaped.
Verification Through Medical Institutions
(1) Hospital pharmacies can assist in verifying the drug’s batch number and supply records.
(2) If unexpected reactions occur after taking the medication (e.g., severe vomiting without nausea), discontinue use immediately and contact the treating physician to verify the drug’s source.
